Hey Pfiz­er, No­var­tis and Eli Lil­ly. G1 Ther­a­peu­tics says it can beat all of you in its $115M IPO

It’s been al­most a year since G1 Ther­a­peu­tics com­plet­ed a $47 mil­lion crossover round. But now the can­cer drug de­vel­op­er says it’s ready for a $115 mil­lion IPO, jump­ing in­to a grow­ing queue on Wall Street with a plan to take on some of the gi­ants in the bio­phar­ma busi­ness.

Re­search Tri­an­gle Park, NC-based G1 is aimed at a well known tar­get in can­cer re­search: CDK 4/6. Pfiz­er scored the pi­o­neer­ing OK for their block­buster drug in 2015, field­ing Ibrance. And No­var­tis fol­lowed up re­cent­ly with Kisqali (peak sales po­ten­tial around $2.5 bil­lion), set­ting up a di­rect clash as Eli Lil­ly pur­sues its own pro­gram for abe­maci­clib.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.